Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III
SNY begins phase III study for its 21-valent pneumococcal conjugate vaccine for treating invasive pneumococcal disease in infants and toddlers.
Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate v...
Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines
Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn into More Strength?
Sanofi (SNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in...
Teva, Sanofi say drug to treat IBD met primary targets
Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn's disease showed it had met primary goals.
SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS
The FDA bestows a Breakthrough Therapy designation to Sanofi's tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis.
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults with no...
Press Release: Availability of the revised financial statements for Sanofi excluding Opella
Availability of the revised financial statements for Sanofi excluding Opella Paris, France – December 6, 2024. Following the press release on October 21, 2024 and the plan to transfer a 50% control...
Sanofi to invest $1 bln in insulin production site in Beijing, local authority says
French drugmaker Sanofi plans to invest 1 billion euros ($1.05 billion) to build a new insulin production base in Beijing, a local authority in the city said on Monday, citing a memorandum of under...
Pharma giant Sanofi opens $595 million vaccine facility in Singapore to boost preparedness for potential pandemics
The facility, known as Modulus, can switch between making different vaccines or treatments in a matter of days. It will contribute about 200 skilled jobs to Singapore, and will be fully operational...
Recordati CEO sees 'substantial opportunity' in Sanofi drug purchase
Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune disorder drug, Enjaymo.
Sanofi: Diverse Drug Portfolio And Future Pipeline, 4% Dividend Yield Looks Attractive
Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse drug portfolio and a robust pipeline of future drugs to market, this big p...
SandboxAQ CEO on the firm's partnership with Sanofi
Jack Hidary, CEO of SandboxAQ, says the firm's partnership with Sanofi aims to drive biomarker discovery in clinical development.
Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales
SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.
Sanofi Q3 earnings beat market view, boosted by vaccine sales
French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by earlier-than-anticipated sales of seasonal vaccines.
Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong bus...
Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
Related Companies